We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
FDA has registered the first targeted therapy for BPDCN — pivekimab sunirin. Remission rate 69.7%, but there are risks. Detailed analysis of the drug and consequences.
